Suppr超能文献

基于明胶的生物材料作为骨肉瘤治疗的递送策略。

Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment.

作者信息

Yang Qifan, Chen Xingpeng, Liu Jing, He Yeteng

机构信息

Department of Orthopedics, The First Hospital of Jilin University, Changchun, China.

Department of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.

出版信息

Front Pharmacol. 2025 Jan 28;16:1537695. doi: 10.3389/fphar.2025.1537695. eCollection 2025.

Abstract

Osteosarcoma is the most common primary malignant bone tumor. Although surgery and chemoradiotherapy have made some progress in the treatment of osteosarcoma. However, the high recurrence and metastasis rate of osteosarcoma and bone defects caused by surgery are still the main problems faced by osteosarcoma. Gelatin has excellent biocompatibility and biodegradability, and has made phased progress in tumor treatment. In the treatment of osteosarcoma, gelatin-based biomaterials can be used in delivery strategies to enhance the anti-tumor activity of osteosarcoma and can improve the appropriate compressive strength to improve the bone defects faced after surgery. At present, gelatin-based hydrogels, gelatin scaffolds, and gelatin-based nanoparticles have been reported in preclinical studies. In this article, we introduce the application of gelatin-based biomaterials in the treatment of osteosarcoma, and summarize and look forward to them.

摘要

骨肉瘤是最常见的原发性恶性骨肿瘤。尽管手术和放化疗在骨肉瘤治疗方面取得了一些进展。然而,骨肉瘤的高复发转移率以及手术造成的骨缺损仍是骨肉瘤面临的主要问题。明胶具有优异的生物相容性和生物降解性,在肿瘤治疗方面已取得阶段性进展。在骨肉瘤治疗中,基于明胶的生物材料可用于递送策略,以增强骨肉瘤的抗肿瘤活性,并能提高适当的抗压强度以改善术后面临的骨缺损。目前,基于明胶的水凝胶、明胶支架和基于明胶的纳米颗粒已在临床前研究中有所报道。在本文中,我们介绍基于明胶的生物材料在骨肉瘤治疗中的应用,并对其进行总结与展望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f72/11811086/bd1619e10fcd/FPHAR_fphar-2025-1537695_wc_sch1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验